Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FMC CORP Capital/Financing Update 2014

Mar 3, 2014

31144_rns_2014-03-03_ad0b49a1-9504-4794-9828-22dcfbfbbb93.zip

Capital/Financing Update

Open in viewer

Opens in your device viewer

8-K 1 fmc030320148k.htm FORM 8-K html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using WebFilings 1 Copyright 2008-2014 WebFilings LLC. All Rights Reserved FMC 03.03.2014 8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________

FORM 8-K

___________

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 28, 2014

______________

FMC CORPORATION

(Exact name of registrant as specified in its charter)

______________

Delaware 1-2376 94-0479804
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
1735 Market Street Philadelphia, Pennsylvania 19103
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 215-299-6000

______________

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-2 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

ITEM 2.01. COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

On February 28, 2014, FMC Corporation (“FMC”) announced the completion of the sale of its FMC Peroxygens business for approximately $200 million in cash to One Equity Partners, the private investment arm of J.P. Morgan Chase and Co.

Attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by this reference, is a copy of FMC's press release dated March 3, 2014, announcing the completion of the disposition. Also attached as Exhibit 99.2 to this Current Report on Form 8-K is the unaudited pro forma financial information. The unaudited pro forma consolidated financial information of FMC was derived from our historical consolidated financial statements and is presented to give effect to the disposition of FMC Peroxygens.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit

Number Description

99.1 Press Release of FMC dated March 3, 2014.

99.2 Pro forma financial information of FMC (Unaudited)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FMC CORPORATION (Registrant)
By: /S/ PAUL W. GRAVES
Paul W. Graves Executive Vice President and Chief Financial Officer

Date: March 3, 2014

EXHIBIT INDEX

Exhibit No. Exhibit Description
99.1 Press Release of FMC dated March 3, 2014.
99.2 Pro forma financial information of FMC (Unaudited)